DS
VTGN icon

David Shaw’s VistaGen Therapeutics VTGN Stock Holding History

David Shaw’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-442
Closed -$12K – 5560
2022
Q2 		$12K Sell
442
-8,658
-95% -$306K ﹤0.01% 5109
2022
Q1 		$339K Buy
9,100
+8,653
+1,936% +$377K ﹤0.01% 4589
2021
Q4 		$26K Sell
447
-2,986
-87% -$194K ﹤0.01% 5279
2021
Q3 		$282K Sell
3,433
-1,392
-29% -$121K ﹤0.01% 4397
2021
Q2 		$456K Buy
+4,825
New +$357K ﹤0.01% 4084

Other funds holding VTGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

David Shaw's VTGN Position: Q3 2022 in Review

David Shaw sold out of VistaGen Therapeutics (VTGN) in Q3 2022, closing a stake of 442 shares — an estimated $12K sold.

David Shaw first reported a position in VTGN in Q2 2021 and held it in 5 quarters. The position peaked at $456K in Q2 2021. 92 funds tracked by Wall St. Rank hold VTGN as of Q3 2022.

  • David Shaw reported no remaining VistaGen Therapeutics position as of Q3 2022 after selling out during the quarter.
  • David Shaw sold 442 VistaGen Therapeutics shares in Q3 2022, an estimated $12K.
  • David Shaw first reported a position in VistaGen Therapeutics in Q2 2021 and held it in 5 quarters.
  • David Shaw's VistaGen Therapeutics position peaked at $456K in Q2 2021.
  • 92 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q3 2022.

Based on D.E. Shaw & Co's 13F filing for Q3 2022, filed 14 Nov 2022.